Trial Profile

Phase II, Single-Arm Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary)
Indications Small cell lung cancer
Focus Therapeutic Use
Acronyms Match
Sponsors Roche

01 Jan 2026 Primary endpoint (Objective Response Rate) has been met, according to the results presented in the International Journal of Radiation Oncology, Biology, Physics.
01 Jan 2026 Results (n=56, data cut-off: June 30, 2024) assessing the synergistic role of low-dose radiation therapy (LDRT) with immunotherapy in the treatment of extensive-stage SCLC (ES-SCLC) presented in the International Journal of Radiation Oncology, Biology, Physics
29 Jul 2024 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com